ENTAEnanta Pharmaceuticals, Inc.
$12.10+9.2% 1Y
$12.10
$10.4752 weeks$16.85
ENTA in its own filings
ENTA's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
206
Events found in the filings · across 832 filings · the record starts in 2012
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 12, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 26, 2012
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 16, 2026
- Late periodic reporthistorical
- 2022-02-10
- SEC comment-letter activity19 occurrences
- 2026-02-17
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 10, 2026Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026.Earnings release · press release
- Jul 2, 2026On July 2, 2026, Enanta Pharmaceuticals, Inc. (the “Corporation”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC, as sales agent (the “Agent”), pursuant to which the Corporation may offer and sell shares (the “Shares”) of its common stock, $0.01 par value per share (“Common …Material agreement entered · Form 8-K
- Jun 23, 2026As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 (the “’953 …Other event · Form 8-K
- Jun 18, 2026Enanta Pharmaceuticals Announces Advancement of its Zelicapavir Clinical Development Program for the.Regulation FD disclosure · press release
- May 11, 2026Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026.Earnings release · press release
- Mar 26, 2026As previously disclosed by Enanta Pharmaceuticals, Inc. (the “Company”), on February 3, 2025, the Company filed a notice of appeal with the United States Court of Appeals for the Federal Circuit relating to its suit against Pfizer Inc. seeking damages for infringement of U.S. Patent No. 11,358,953 in the manufacture …Other event · Form 8-K
- Mar 12, 2026, on March 11, 2026, the stockholders of Enanta Pharmaceuticals, Inc. approved an amendment to its 2019 Equity Incentive Plan to increase the number of shares reserved for issuance thereunder by 1,600,000 shares.Director or officer change · Form 8-K
- Feb 9, 2026Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter.Earnings release · press release
- Nov 17, 2025Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025.Earnings release · press release
- Oct 1, 2025Public Offering On September 30, 2025, Enanta Pharmaceuticals, Inc. (“Enanta”) entered into an underwriting agreement (the “Underwriting Agreement”) with J.P. Morgan Securities LLC, Jefferies LLC, and Evercore Group L.L.C., as representatives of the several underwriters named therein (collectively, the …Other event · Form 8-K
- Sep 29, 2025Phase 2b Study of Zelicapavir in.Regulation FD disclosure · press release
- Sep 29, 2025Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…